


# CONTENTS

## MEDICAL SCIENCES



### **Medical Sciences - Volume 1**

**No. of Pages:** 532

**ISBN:** 978-1-84826-283-6 (eBook)

**ISBN:** 978-1-84826-733-6 (Print Volume)

### **Medical Sciences - Volume 2**

**No. of Pages:** 516

**ISBN:** 978-1-84826-284-3 (eBook)

**ISBN:** 978-1-84826-734-3 (Print Volume)

For more information on e-book(s) and Print Volume(s) order, please [click here](#)

[Or contact : eolssunesco@gmail.com](mailto:eolssunesco@gmail.com)

## CONTENTS

### VOLUME I

#### **Modern Medical Practices: A Commentary** **1**

Guy J. Lavoipierre, *Former Epidemiologist, World Health Organization, Geneva, Switzerland*

1. Modern Medical Practices : A Commentary
2. Medical Practices In Economically Developed Countries
  - 2.1. Changing Morbidity
  - 2.2. General Medical Practice
3. General medical practice and training of medical students
4. Laboratory investigations, medical malpractice and cost of health care delivery
5. Patients' Expectations, The 'Magic Pill Syndrome' and Lifestyle-Inflicted Illnesses
  - 5.1. Patients' expectations
  - 5.2. The 'magic pill' syndrome and lifestyle illnesses
6. Prevention and the general practitioner
7. Modern medical practice and unconventional therapies
8. Politicians and medical practice
9. Modern medical practice and the pharmaceutical industry
10. Medical Practice In Underprivileged And Developing Countries
11. Indoor air pollution control as an illustration
12. Health care delivery in remote zones
13. Conclusion

#### **Reflections on the Scientific Method in Medicine** **23**

Rodolfo J. Stusser, *Former Consultant Researcher and Professor of National Research Centers of Havana University, Ministry of Public Health, and West Havana Scientific Productive Pole, Havana, Cuba.*

1. Background
  - 1.1. The approach to a scientific method in clinical medicine
  - 1.2. How the current situation developed
2. Essential methodological principles
3. Logical and methodological problems of clinical medicine science
4. Suggestions to improve medical scientific methodology
  - 4.1. Creation of an integrative medical scientific methodology
  - 4.2. Use of a "recombinant" hypothesis-discovery support system
  - 4.3. Use of a modeling and simulation research design optimizer
  - 4.4. Enhancement of clinical scientific hypothesis creativity
5. Underlying theoretical and philosophical problems of medical science
6. Unified methodological system for investigation in medicine
  - 6.1. A trans-methodological model of clinical, basic and health sciences
  - 6.2. Re-unification of clinical scientific method for practice and research
7. Conclusions and Recommendations

#### **Technology for Health and Medicine** **48**

Pierre Boutros Mansourian, *Former Director (ret.), Research Policy Coordination, WHO / HQ- Geneva, Switzerland*

1. Introduction
2. Science, Technology and Medicine
3. Science and Technology Disparities
4. Health Disparities
5. Global Costs of Health Technology

6. Avenues in Technological Development
  - 6.1. Major Advances
  - 6.2. Gene Technology and Medicines
  - 6.3. Engineering in Medicine
7. Conclusion

**Public Health - An Evolving Concept**

**60**

Lennart Kohler, *Nordic School of Public Health, SE-402 42 Göteborg, Sweden*

1. The task of Public Health and its development
2. The concept of health
3. Actual problems of the modern health care systems
  - 3.1. Major Changes in the Disease Panorama
  - 3.2. Resource Constraints and the Infinity of Demand for Services
  - 3.3. Unequal Distribution of Resources and Utilization of Care
  - 3.4. Quality of Care and Sensitivity to Patients
4. The response of the modern Public Health
5. Shifting focus of Public Health
  - 5.1. The Movement from Old to New Public Health
  - 5.2. Health Protection and Promotion
  - 5.3. Comprehensive Public Health
6. Principal areas of Public Health
  - 6.1. Education
  - 6.2. Research
  - 6.3. Practice
7. Challenges
  - 7.1. The Artificial Separation of Medicine and Public Health
  - 7.2. The Need for a Broad View on the Citizen's Health
8. Forward
  - 8.1. Strategies to Strengthen the Role of Public Health
9. Concluding remarks on the health of populations and the role of Public Health

**Public health Surveillance**

**75**

Laura R. Johnson, *Emory University School of Medicine, Atlanta, Georgia, USA*  
 David L. Heymann, *World Health Organization, Geneva, Switzerland*

1. Introduction
2. History of Surveillance
3. Background on the Modern Concept of Surveillance
  - 3.1. The Case Definition
  - 3.2. Data Collection
  - 3.3. Data Management and Analysis
  - 3.4. Data Dissemination
  - 3.5. Evaluation of Surveillance Systems
4. Source of Surveillance Information
  - 4.1. The Patient Treatment Record
  - 4.2. The Population Survey
  - 4.3. Networks for Outbreak Detection and Reporting
5. Conclusion

**Environment and Public Health**

**93**

P. Hartemann, *Nancy University School of Medicine, Nancy, France*

1. Introduction
2. Hazards and Risks Perception

3. Faring Classical Hazards
  - 3.1. Water
    - 3.1.1. Water Resources
    - 3.1.2. Drinking Water
  - 3.2. Air
    - 3.2.1. Air Pollution
    - 3.2.2. Indoor Air Pollution
  - 3.3. Toxic Chemicals and Hazardous Waste Disposal
  - 3.4. Noise
4. Emerging Risks and Global Environmental Change
5. Conclusion

**Maternal And Child Health: A Basic Part Of Public Health**

**117**

Mark A. Belsey, *Consultant in International Health and Development, New York, USA (World Health Organization -Retired)*

1. Introduction
2. The Historical Context
  - 2.1. In Ancient Times and Traditional Societies
  - 2.2. MCH in an Era of Scientific Discovery and Social Concerns
3. The Elements and Technologies of MCH
4. Indicators and Information Systems for Maternal and Child Health
5. The Organization and Management of MCH Services
6. Setting Policies for MCH and the Health of Women, Children and Families
7. Conclusion: The Challenges for the Future

**Public Health Ethics for Today and Tomorrow**

**142**

M. Manciaux, *School of Public Health, University of Nancy, France*

G. Terrenoire, *Social scientist, National Center for Scientific Research (CNRS), France*

1. Introduction
2. Public Health
  - 2.1. From Mythology to Modernity
  - 2.2. Definitions and Charters
3. Ethics
  - 3.1. How should we act?
  - 3.2. Bioethics
  - 3.3. International Guidelines and Codes
4. From Bioethics to Public Health Ethics
  - 4.1. Convergences
  - 4.2. Turning Points
  - 4.3. Towards Codification
5. Current Challenges
  - 5.1. Equal Rights, Unequal Needs and Access
  - 5.2. Cultural Diversity
  - 5.3. The North-South Ethical Gap
  - 5.4. Efficiency vs. Ethics
  - 5.5. Information and Communication
  - 5.6. Precautionary Principle
  - 5.7. Ethical Issues in day-to-day Public Health Work
6. Ethics for Public Health Tomorrow

**Geographic Medicine: An Introduction**

**161**

Yola L. G. Verhasselt, *Free University of Brussels, Belgium*

1. Introduction

2. Topical Highlights
  - 2.1. Health Disparities, as a Reflection of Globalization and Fragmentation of the Contemporary World
  - 2.2. The Geography of Health Care Systems
  - 2.3. Environmental Change and Vector-Borne Diseases: The Contribution of Remote Sensing and Spatial Analyses
  - 2.4. Bio-Environmental Correlates of Chagas' Disease.
3. Concept Evolution
4. Urbanization and Health
5. Ageing
6. Development and Health
7. Migration
8. Concluding Remarks

### **The Geography of Health Care Systems**

**169**

David R. Phillips, *Lingnan University, Tuen Mun, Hong Kong*

Mark W. Rosenberg, *Queen's University, Kingston, Ontario, Canada*

Kathleen Wilson, *University of Toronto at Mississauga, Mississauga, Ontario, Canada*

1. Introduction
2. Defining a Health Care System
3. Access to Health Care Services
4. Restructuring Health Care Systems
5. New Spaces of Health Care Delivery
6. Conclusions

### **Disparities in Health : A Reflection of the Worlds Globalisation and Fragmentation**

**181**

Jeanne-Marie Amat-Roze, *Department of Geography, Paris 12 University, France*

1. Introduction
2. Undeniable convergence
  - 2.1. « *Unheard-of* » Statistics in Human History
  - 2.2. A Worldwide Struggle
3. Increased globalisation of health needs
  - 3.1. The Threat of New Infectious Pandemics
  - 3.2. Worldwide Epidemic of Non-infectious Diseases
4. But a powerful dynamic of divergence
  - 4.1. Gender-based Disparities
  - 4.2. Appearance of Extreme Disparities Between Nations
5. The singular case of sub-Saharan Africa
6. The rise of a global underprivileged class
  - 6.1. A Fall in Extreme Poverty but a Rise in Inequalities
  - 6.2. Socio-territorial Health Disparities
7. Conclusion

### **Environmental Change and Vector-Borne Diseases: The Contribution of Remote Sensing and Spatial Analyses**

**202**

Sophie O. Vanwambeke and Eric F. Lambin, *Department of Geography, Université catholique de Louvain, Belgium*

1. Vector-borne disease in the 21st century
2. Vector-borne diseases and environmental change
3. People, vectors and landscape: A conceptual model
  - 3.1. People and Landscape
  - 3.2. People and Vectors

- 3.3. Vectors and Landscape
4. Remote sensing systems: A tool for studying the environment
  - 4.1. Land Surface Attributes Measured by Remote Sensing
    - 4.1.1. In the Spectral Domain
    - 4.1.2. In the Spatial Domain
  - 4.2. Processing and Analysis of Remotely Sensed Data
    - 4.2.1. Pre-processing
    - 4.2.2. Image Classification
    - 4.2.3. Change Detection
5. Remote sensing and vector-borne diseases
  - 5.1. Examples of Use of Remotely-sensed Data for the Study of Vvector-borne Diseases
    - 5.1.1. High-resolution Remotely-sensed Data Applications
    - 5.1.2. Low-resolution Remotely-sensed Data Applications
6. Spatial dimension of disease transmission and Geographical Information Systems
  - 6.1. Components of a Geographic Information System
  - 6.2. Examples of Spatial Analyses in Epidemiology
7. Conclusions

**Bioenvironmental Correlates of Chagas' Disease**

**219**

Susana Isabel Curto, *National Council for Scientific and Technological Research, Institute of Epidemiological Research, National Academy of Medicine – Buenos Aires. Argentina.*

1. Introduction
2. Biological members and transmission dynamics of disease
3. Interconnection of wild, peridomestic and domestic cycles
4. Dynamic of domiciliation of the vectors: origin and diffusion of the disease
5. The rural housing as environmental problem
6. Bioclimatic factors of Triatominae species
7. Description of disease
8. Rates of human infection
9. Conclusions

**Adult Congenital Heart Disease: A Challenging Population**

**233**

Khalid Aly Sorour, *Cairo University, Kasr el-Aini Hospital, Egypt*

1. Introduction
2. Epidemiology of Congenital heart disease
3. Types of adult patients with CHD
4. Congenital heart disease in adults – Unoperated survival
  - 4.1. Common Defects with Expected Adult Survival
  - 4.2. Common Defects with Exceptional Adult Survival
  - 4.3. Uncommon Defects with Expected Adult Survival
  - 4.4. Uncommon Defects with Exceptional Adult Survival
5. Why do we need specialized centers for the care of adults with CHD?
6. Transfer from pediatric to adult services
7. Organization of services and care
8. Conclusions

**Advances and Prospects in Gastroenterology**

**241**

Witold Bartnik, *Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education, Warsaw, Poland*

1. Introduction
2. Diagnostic tests in gastroenterology
3. Upper gastrointestinal diseases
  - 3.1. Gastro-esophageal Reflux Disease (GERD)

- 3.1.1. Complications of GERD
- 3.2. Gastric Cancer
- 3.3. Peptic Ulcers and Their Complications
- 3.4. Dyspepsia
- 4. Diseases of the intestines
  - 4.1. Acute Infectious Diarrhea (by Hanna Szajewska, M.D., *Department of Pediatric Gastroenterology and Nutrition, The Medical University of Warsaw, Warsaw, Poland*)
  - 4.2. Celiac Disease
  - 4.3. Irritable Bowel Syndrome
  - 4.4. Lower Gastrointestinal Bleeding
  - 4.5. Inflammatory Bowel Disease (IBD)
    - 4.5.1. Treatment of IBD
  - 4.6. Colorectal Cancer
    - 4.6.1. Screening for Colorectal Neoplasms
    - 4.6.2. Chemoprevention of Colorectal Cancer
- 5. Diseases of the pancreas
  - 5.1. Acute Pancreatitis
  - 5.2. Chronic Pancreatitis
  - 5.3. Pancreatic Cancer
- 6. Diseases of the liver
  - 6.1. Hepatitis B
  - 6.2. Hepatitis C
  - 6.3. Non-alcoholic Fatty Liver Disease (NAFLD)
  - 6.4. Hepatocellular Carcinoma
- 7. Impact of genomics in gastroenterology and hepatology

**Obstetrics And Gynaecology**

**263**

A. Himaya, *Former Consultant Obstetrician and Gynaecologist, University of Ottawa, Ottawa, Canada.*

- 1. Definition of Obstetrics
- 2. History of Obstetrics
- 3. Infectious Diseases in the Pregnant Woman
- 4. Normal Pregnancy
- 5. Pregnancy Complications
  - 5.1. Maternal Complications
  - 5.2. Fetal Complications
- 6. Delivery
- 7. What is Gynaecology
- 8. History of Gynaecology
- 9. The Vulva
- 10. The Vagina
- 11. The Uterus

**Probiotic A Novel Approach To Treating Childhood Atopy**

**323**

Aziz Koleilat, *Department, Makassed University General Hospital. Riad EI-Solh 110722 10. Beirut – Lebanon*

- 1. Introduction
- 2. Mechanisms of action of Probiotic
- 3. The aims of intervention
- 4. Clinical Context
- 5. How Probiotics Work?
- 6. Probiotics & Atopy
  - 6.1. Causes, Prevention and Treatment
  - 6.2. Who is at risk?
  - 6.3. The relationship between food allergy and atopic dermatitis
  - 6.4. Strategies for a primary prevention of atopy

- 6.5. Use of Probiotics in Atopic Diseases
- 7. Conclusions

**Overview of Pathology and its Related Disciplines**

336

Soheir Mahmoud Mahfouz, *Cairo University, Kasr El Ainy Hospital, Egypt*

- 1. Introduction
  - 1.1. Pathology coverage
    - 1.1.1. Etiology and Pathogenesis of a Disease
    - 1.1.2. Manifestations of Disease (Lesions)
    - 1.1.3. Phases Of A Disease Process (Course)
  - 1.2. Physician's approach to patient
  - 1.3. Types of pathologists and affiliated specialties
  - 1.4. Role of pathologist
- 2. Pathology and its related disciplines
  - 2.1. Cytology
    - 2.1.1. Cytology Samples
    - 2.1.2. Technical Aspects
    - 2.1.3. Examination of Sample and Diagnosis
- 3. Pathology techniques and ancillary diagnostic methods
  - 3.1. Macroscopic pathology
  - 3.2. Light Microscopy
  - 3.3. Polarizing light microscopy
  - 3.4. Electron microscopy (EM)
  - 3.5. Confocal Microscopy
  - 3.6. Frozen section
  - 3.7. Cyto/histochemistry
  - 3.8. Immunocyto/histochemical methods
  - 3.9. Molecular and genetic methods of diagnosis
  - 3.10. Quantitative methods
- 4. Types of tests used in Pathology
  - 4.1. Diagnostic tests
  - 4.2. Quantitative tests
  - 4.3. Prognostic tests
- 5. The scope of Pathology and its main divisions
- 6. Conclusions

**The Pathobiology of Bilharzia-Associated Bladder Cancer**

360

Nadia Mahmoud Mokhtar, *Department of Pathology National Cancer Institute(NCI). , Cairo University, Egypt*

Nabil El Bolkainy, *National Cancer Institute NCI , Cairo University Egypt*

Hussein Khaled, *National Cancer Institute NCI , Cairo University Egypt*

Abdul Rahman Zekri, *Department of Cancer Biology at the National Cancer Institute NCI , Cairo University Egypt*

- 1. Introduction
- 2. Precursor Lesions
- 3. Classification
  - 3.1. Transitional Cell Carcinoma
  - 3.2. Papillary Transitional Neoplasm of Low Malignant Potential
  - 3.3. Papillary Transitional Carcinoma
  - 3.4. Invasive Transitional Carcinoma
  - 3.5. Squamous Cell Carcinoma
  - 3.6. Adenocarcinoma
  - 3.7. Undifferentiated Tumors
  - 3.8. Rare Variants
- 4. Early detection and chemoprevention

5. Biologic features
  - 5.1. Chromosomal Changes
  - 5.2. Cancer Genes
  - 5.3. P53
  - 5.4. Mdm2
  - 5.5. Proliferation and cell cycle markers
  - 5.6. Ras
  - 5.7. Other Biologic Markers
  - 5.8. Viruses
6. Conclusion

**Bilharziasis: A Granulomatous Parasitic Disorder with Grave Implications**

**374**

Maha Mahmoud Akl, *Department, Theodor Bilharz Research Institute (affiliated to Ministry of High Education and Scientific Research). Kornish El Nile. Warak El Hadar, Embaba, Cairo. Egypt P.O.Box 30. Postal Code: 12411.*

1. Introduction
  - 1.1. Discovery of schistosomes ( Bilharzia worms) by Theodor Bilharz
2. Life cycle of the Bilharzial parasite
  - 2.1. Schistosomiasis species and their stages
  - 2.2. Asexual part of life cycle (intermediate host phase)
  - 2.3. Sexual part of the cycle
  - 2.4. Eggs
3. Pathogenesis of schistosomiasis
  - 3.1. Eggs
  - 3.2. Egg granulomas
  - 3.3. Mechanisms underlying granuloma formation
  - 3.4. Pathological stages of schistosomiasis
4. Clinical features of Bilharziasis due to Schistosoma mansoni infection
  - 4.1. Skin Lesions
  - 4.2. Acute schistosomiasis
    - 4.2.1. Katayama fever
    - 4.2.2. Symptoms of the acute stage
    - 4.2.3. Treatment of Acute Phase
  - 4.3. Intestinal Schistosomiasis (Bilharziasis); chronic stage
    - 4.3.1. Mild and early intestinal lesions
    - 4.3.2. Severe and prolonged cases develop specific pathological lesions which include
      - 4.3.2.1. Bilharzial polyps
      - 4.3.2.2. Sandy patches
      - 4.3.2.3. Bilharzial ulcers
      - 4.3.2.4. Intestinal fibrosis
  - 4.4. Complications of Intestinal Bilharziasis: Includes the following
  - 4.5. Symptoms of Intestinal Bilharziasis
  - 4.6. Treatment of Intestinal Bilharziasis
5. Hepatosplenic Bilharziasis (Bilharzial hepatic portal fibrosis)
  - 5.1. Pathogenesis and Pathology of Bilharzial Hepatic Fibrosis
    - 5.1.1. The Portal Tracts show major changes
    - 5.1.2. The Hepatic Lobules
    - 5.1.3. Gross Features of the Affected Livers by Bilharziasis
  - 5.2. Classification of Bilharzial Portal Fibrosis
    - 5.2.1. Fine bilharzial periportal fibrosis
    - 5.2.2. Coarse bilharzial periportal fibrosis
  - 5.3. Effects of Bilharzial Portal Fibrosis and Its Complications
  - 5.4. Causes of Death in Hepatic Bilharziasis
    - 5.4.1. Pathogenesis of Splenic Enlargement
    - 5.4.2. Effects and Complications of Splenomegaly
6. Bilharziasis of the urogenital system
  - 6.1. Bilharzial Cystitis

- 6.2. Pathogenesis of Bilharzial Cystitis
- 6.3. Complications of Urinary Bilharziasis
- 6.4. Bilharziasis of Other Parts of the Uro-Genital System
  - 6.4.1. Bilharziasis of the Ureter
  - 6.4.2. Bilharziasis of the Male Genital Organs
  - 6.4.3. Bilharziasis of Female Genital Organs
  - 6.4.4. Impact of bilharziasis on bladder cancer pathology
7. Bilharziasis of the lungs
  - 7.1. Pathogenesis of Lung Bilharziasis
    - 7.1.1. Pathological Features of Lung (Pulmonary) Bilharziasis
    - 7.1.2. Effects and Complications of Pulmonary Bilharziasis
8. Bilharziasis of Other Organs
9. Schistosomal Antigens and Immune Complexes
10. Conclusion

### **The Pathology Of Breast Cancer**

401

Ali Ahmed Foad El Hindawi, *Cairo University. Kasr El Ainy Hospital. Egypt.*

1. Introduction
2. Types of breast lumps
3. Breast carcinoma
  - 3.1. In Situ Carcinoma of the Mammary Gland
    - 3.1.1. Lobular Neoplasia (LN)
    - 3.1.2. Duct Carcinoma in Situ (DCIS)
  - 3.2. Invasive Carcinoma of the Mammary Gland
    - 3.2.1. Microinvasive Carcinoma of the Mammary Gland
    - 3.2.2. Invasive Lobular Carcinoma (ILC)
    - 3.2.3. Invasive Duct Carcinoma
  - 3.3. Paget's Disease of the Nipple
  - 3.4. Bilateral Breast Carcinoma
4. Conclusions

### **Medical Informatics and Telematics at the Threshold of the 21st Century**

423

Lun Kwok Chan, *Past President, International Medical Informatics Association (IMIA) and Professor (Adjunct), School of Biological Sciences, Nanyang Technological University, Singapore*  
 G. W. Brauer, *Associate Professor, School of Health Information Science, University of Victoria, Canada and Member of the International Commission on the development of EOLSS Theme on Medical Sciences*

1. Introduction
2. Brief History
3. Institution-centered Informatics
  - 3.1. Hospital Information Systems
  - 3.2. Picture Archiving and Communication Systems
4. Patient-centered Informatics
  - 4.1. Electronic Patient / Medical Record
  - 4.2. Knowledge Management / Decision Support
5. Community-centred Informatics
  - 5.1. Disease Surveillance
  - 5.2. Telehealth / Telemonitoring
6. Standards in Medical Informatics
7. Data Security, Confidentiality and Privacy in Medical Informatics
8. Medical and Health Informatics Education
  - 8.1. Curriculum Content
  - 8.2. Course Tracks Imbedded in non-MI Programs
  - 8.3. Dedicated MI Programs
  - 8.4. Modes of Delivery in MI Education

9. Promoting Medical Informatics
  - 9.1. Professional Organizations
  - 9.2. Conferences
  - 9.3. Yearbook and Journals
  - 9.4. Web Resources
  - 9.5. Textbooks

<b>The Past and Future Impacts of Health/Medical Informatics on HealthCare Delivery</b>	<b>454</b>
<i>Denis J. Protti, School of Health Information Science, University of Victoria, B.C., Canada</i>	

1. Introduction
2. The Use of Computers in Health Care Is Reducing Errors and Improving Patient Safety
3. The Benefits of a Unified Electronic Health Record
4. Computer Technology in Primary Care and Chronic Disease Management
5. Using Communications Technology to Traverse Space at the Speed of Care
  - 5.1. Tele-Semantics
  - 5.2. Tele-Informatics in Practice
6. Conclusion

<b>Index</b>	<b>469</b>
--------------	------------

<b>About EOLSS</b>	<b>479</b>
--------------------	------------

## VOLUME II

<b>Human Aspects Of Health Care Information Systems</b>	<b>1</b>
<i>Andre Kushniruk, School of Health Information Science, University of Victoria, Victoria, British Columbia, Canada</i>	
<i>Joseph Kannry, Mt. Sinai Medical Center, New York, New York, U.S.A.</i>	

1. Introduction
2. Background
  - 2.1. The Study of Human-Computer Interaction
  - 2.2. Cognitive Aspects of HCI in Health Care
  - 2.3. Human Information Processing and Distributed Cognition
  - 2.4. Skilled Performance, Expertise and Learning
  - 2.5. Perception and Attention
  - 2.6. User Interaction Style
  - 2.7. Principles for Displaying Information
  - 2.8. Data Entry
  - 2.9. General User Interface Principles in Health Care
3. Towards a Framework for Considering HCI in Health Care
4. Human-Computer Interaction and the System Development Life Cycle
5. Usability Engineering Methods for the Iterative Evaluation and Improvement of Health Information Systems
  - 5.1. Usability and Usability Testing in Health Care
  - 5.2. Usability Inspection in Health Care
  - 5.3. Modeling of Health Care Workflow
6. Examples of Emerging Technologies in Health Care User-Computer Interfaces
  - 6.1. Visualization of Health Care Data
  - 6.2. Web-based Systems
  - 6.3. Pervasive Computing in Healthcare
  - 6.4. Cooperative Work Environments
  - 6.5. Customizable and Adaptive User Interfaces

7. Conclusion – Need for Cognitive Approaches to System Design in Health Care

**Clinical Informatics** **17**

Andre Kushniruk, *School of Health Information Science, University of Victoria, Victoria, British Columbia, Canada*

Joseph Kannry, *Mt. Sinai Medical Center, New York, New York, U.S.A.*

1. Introduction
2. Background: The Origins of Clinical Informatics
3. The Emergence of Healthcare Information Technology and the Electronic Health Record (EHR)
  - 3.1. Ideal Features of Electronic Health Record Systems
  - 3.2. Technical Requirements of Electronic Health Record Systems
4. Issues with Electronic Health Record Systems
5. Emergence of Clinical Decision Support Systems (CDSS) and On-line Clinical Guidelines
6. Monitoring Systems
7. Clinical Departmental Systems
8. Hospital-Wide Clinical Information Systems
9. Discussion
10. Conclusion

**Tissue Engineering** **27**

Robert M. Nerem, *Georgia Tech/Emory Center for the Engineering of Living Tissues*

*Parker H. Petit, Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332-0363, USA*

1. Introduction
2. Clinical Applications
3. Cell Source: All Cells are not Created Equal
4. Other Critical Issues
5. From Benchtop Research to a Product and to the Patient
6. The Future

**Biomaterials** **43**

Eileen Gentleman, Michael D. Ball, Molly M. Stevens, *Department of Materials, Imperial College London, London SW7 2AZ, UK*

1. Introduction
  - 1.1. History of Biomaterials
  - 1.2. Materials in Medicine
2. Types of Materials
  - 2.1. Metals
    - 2.1.1. 316L Stainless Steel
    - 2.1.2. Commercially Pure Titanium and Titanium Alloys
    - 2.1.3. Cobalt-Chromium Alloys
  - 2.2. Ceramics
    - 2.2.1. Bioinert Ceramics
      - 2.2.1.1. Pyrolytic Carbon
      - 2.2.1.2. Alumina
      - 2.2.1.3. Zirconia
    - 2.2.2. Bioactive Ceramics
    - 2.2.3. Biodegradable Ceramics
  - 2.3. Polymers
    - 2.3.1. Bioinert Polymers
      - 2.3.1.1. Polyethylene (PE)
      - 2.3.1.2. Polytetrafluorethylene (PTFE)

- 2.3.1.3. Polyethylene Terephthalate (PET)
    - 2.3.1.4. Polymethylmethacrylate (PMMA)
    - 2.3.1.5. Polysiloxanes
    - 2.3.1.6. Other
  - 2.3.2. Bioresorbable Polymers
    - 2.3.2.1. Hydrogels
    - 2.3.2.2. Polyglycolic Acid (PGA)
    - 2.3.2.3. Polylactic acid (PLA)
    - 2.3.2.4. Other
    - 2.3.2.5. Natural Bioresorbable Polymers
- 2.4. History of Biomaterials
- 2.5. Materials in Medicine
- 3. Tissue/Biomaterials Interactions
  - 3.1. Protein Interactions
  - 3.2. Coagulation
  - 3.3. Acute Inflammation
  - 3.4. Wound Healing
  - 3.5. Immune Responses
  - 3.6. Foreign Body Reaction
  - 3.7. Non-Specific Cell Responses
- 4. Uses of Biomaterials
  - 4.1. Connective Tissues
    - 4.1.1. Bone
    - 4.1.2. Joints
    - 4.1.3. Ligament and Tendon
    - 4.1.4. Dental
    - 4.1.5. Soft Tissue Repair and Augmentation
    - 4.1.6. Sutures
  - 4.2. Sensory Tissues
    - 4.2.1. Nervous
    - 4.2.2. Ocular
      - 4.2.2.1. Contact Lenses
      - 4.2.2.2. Artificial Vitreous Humour
      - 4.2.2.3. Scleral Buckling Materials
      - 4.2.2.4. Intraocular Lenses
    - 4.2.3. Auditory
  - 4.3. Metabolic Tissues
    - 4.3.1. Kidney
    - 4.3.2. Liver
    - 4.3.3. Pancreas
  - 4.4. Cardiovascular Tissues
    - 4.4.1. Replacement Heart Valves
    - 4.4.2. Cardiac Assist Devices
    - 4.4.3. Artificial Blood Vessels
    - 4.4.4. Stents
  - 4.5. Drug Delivery
  - 4.6. Tissue Engineering
  - 4.7. Protein Interactions
  - 4.8. Coagulation
  - 4.9. Acute Inflammation
  - 4.10. Wound Healing
  - 4.11. Immune Responses
  - 4.12. Foreign Body Reaction
  - 4.13. Non-Specific Cell Responses
- 5. Challenges for Biomaterials
  - 5.1. Thrombus/Embolus
  - 5.2. Corrosion
  - 5.3. Wear

- 5.4. Infection
- 5.5. Calcification
- 5.6. Tumourigenicity
- 5.7. Hypersensitivity
- 5.8. Systemic Toxicity
- 5.9. Mechanical Failure
- 5.10. Poor Biocompatibility
6. Next Generation Biomaterials
7. Conclusions

**Robotics In Surgery – Past, Present And Future**

**86**

Rajesh Aggarwal, *Department of Biosurgery and Surgical Technology, Imperial College London, UK*  
 Ara Darzi, *Department of Biosurgery and Surgical Technology, Imperial College London, UK*  
 Guang-Zhong Yang, *Royal Society/Wolfson Medical Image Computing Laboratory, UK*

1. Introduction
2. Limitations of Laparoscopic Surgery
3. The Development of Robotic Systems in Surgery
4. The Impact of Robotic Systems in Surgery
5. Robotics for Gastrointestinal Surgery
6. Robotics for Cardiac Surgery
7. Robotics for Urological Surgery
8. Training Programs for Robotic Surgery
9. Development of a Robotic Credentialing Program
10. Telerobotics, Telementoring and Telepresence
11. Conclusion

**Physiological Measurement**

**110**

Nigel H. Lovell, *Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia*  
*National Information and Communications Technology Australia (NICTA), Australian Technology Park, Eveleigh, Australia*  
 Dean M Karantonis, *Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia*  
 Shaun L Cloherty, *Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia*  
 Branko G Celler, *School of Electrical Engineering and Telecommunications, University of New South Wales, Sydney, Australia*

1. Introduction
2. Biomedical Signals and Measurement Systems
  - 2.1. Biomedical Signals
  - 2.2. Biomedical Instrumentation Overview
3. Physical Measurements
  - 3.1. Flow and Volume Measurement
    - 3.1.1. Blood Flow Measurement
    - 3.1.2. Volume Measurement
  - 3.2. Pressure and Force Measurement
    - 3.2.1. Sensing Elements
    - 3.2.2. Invasive Pressure Sensors
    - 3.2.3. Non-invasive Pressure Measurement
    - 3.2.4. Force Measurement
  - 3.3. Measurement of Motion (Displacement, Velocity and Acceleration)
  - 3.4. Chemical Measurement
    - 3.4.1. Optically-based Sensors
    - 3.4.2. Electrochemical Sensors

- 3.5. Bioelectric Measurement
  - 3.5.1. Origin of Bioelectric Potentials
  - 3.5.2. Biopotentials and their Applications
  - 3.5.3. Biopotential Electrodes and Instrumentation
- 3.6. Measurement of Thermal Radiation
4. Conclusion

### **Nanobiotechnology**

**159**

*C. Ruggiero, Department of Communication Computer and System Sciences, University of Genoa, Italy*

1. Microtechnology and Nanotechnology
2. The Dawning of Nanotechnology
3. Nanoscale Structures: Technology and Applications
4. A Key Instrument For Nanotechnology: The Scanning Tunnelling Microscope
5. Nanotechnology And Government Policies
6. The Impact of Nanotechnology on Biology and Medicine: Nanobiotechnology
7. Assemblies of Organized Biomolecules and Nanoparticles: Ultra Thin Films
  - 7.1 Langmuir Blodgett Techniques
  - 7.2 Processing from A Solution: Spin Coating and Solution Casting
  - 7.3 Chemical Self-Assembly
  - 7.4 Layer-By-Layer Self-Assembly
8. Carbon Nanotubes
  - 8.1 Properties of CNTs
  - 8.2 Biomedical Applications of Cnts
    - 8.2.1 Sensors
    - 8.2.2 Drug Delivery
    - 8.2.3 Implantable Nanorobot, Nanosensors and Devices
    - 8.2.4 Radiation oncology
9. High-Throughput Genomic and Proteomic Analysis: DNA Microarrays and Protein Antibody Microarrays
  - 9.1 DNA Microarrays
  - 9.2 Protein and Antibody Microarrays
10. Nanoparticles
  - 10.1 Preparation of Nanoparticles
  - 10.2. The Artificial Cell

### **House Dust Mites-What Might A Mite Do?**

**182**

*Nadia Aly El-Dib, Faculty of Medicine, Cairo University, Egypt.*

1. Introduction
2. Taxonomy and natural history of house dust mites
3. Morphology of dust mites
4. Life stages of dust mites
5. Ecology and habits
  - 5.1. Feeding Habits
  - 5.2. Excretion of Faecal Pellets
  - 5.3. Hosts
6. Effect on health
  - 6.1. Environmental Factors associated with Increasing Sensitivity to Mite Allergens
7. The common sites for house dust mites
8. Exposure to house dust mite allergens
9. The familiar signs and symptoms of airborne allergies
  - 9.1. Allergic Rhinitis
  - 9.2. Conjunctivitis
  - 9.3. Dermatitis
  - 9.4. Bronchial Asthma
10. Diagnosis

11. Managing dust mite's allergy
  - 11.1. Treatment of the Patient
  - 11.2. Modification of the Patient's Environment
    - 11.2.1. Furnishing
    - 11.2.2. Floors
    - 11.2.3. Beds
    - 11.2.4. Stuffed Furry Toys
    - 11.2.5. Indoor Humidity Control
    - 11.2.6. Vacuum Cleaning
    - 11.2.7. Air Purifiers
    - 11.2.8. Insecticide (Acricides)
12. Conclusion

**Tropical Health: A Global Challenge**

**194**

Refaat Kamel, *Ain Shams University, Egypt.*

1. Introduction
2. Medical Conditions in the Tropics
  - 2.1. Infections
  - 2.2. Non-infectious Tropical Surgical Conditions
  - 2.3. Emergencies in the Tropics
    - 2.3.1. Surgical Emergencies in the Tropics
    - 2.3.2. Obstetric Emergencies in the Tropics
3. Anaemia in Tropical Areas
4. Global Warming: The Hidden Health Risk
5. Low Cost
6. Conclusion and Hope for the Future

**Food Safety – Its Role In Health And Development: The Problems Related To Our Food Supply**

**207**

Fritz K. Kaferstein, *International Food Safety Consultant, Nyon, Switzerland*

Yasmine Motarjemi, *Food Safety Manager, Nestlé, S.A., Vevey, Switzerland*

Gerry Moy, *GEMS/Food Manager, World Health Organization, Geneva, Switzerland*

1. The problems related to our food supply
  - 1.1. Introduction
  - 1.2. Biological hazards
  - 1.3. Chemical hazards
    - 1.3.1. Introduction
    - 1.3.2. Food Additives
    - 1.3.3. Veterinary Drug Residues
    - 1.3.4. Pesticide Residues
    - 1.3.5. Environmental Chemicals
    - 1.3.6. Processing Contaminants
    - 1.3.7. Mycotoxins
    - 1.3.8. Marine Biotoxins
    - 1.3.9. Plant Toxicants
    - 1.3.10. Biogenic Amines
  - 1.4. Physical Hazards
  - 1.5. Hazards caused by the absence of certain substances in food
  - 1.6. Emerging biological hazards
  - 1.7. Concern regarding emerging food technologies
  - 1.8. Food Allergy and Intolerance
  - 1.9. International Efforts Regarding Food Safety
  - 1.10. Factors of Significance for Food Safety
    - 1.10.1. Health and Demographics

- 1.10.2. Food Supply Systems
- 1.10.3. Health Systems and Infrastructure
- 1.10.4. Social Situations, Behaviors, and Lifestyles
- 1.10.5. Environmental Conditions
- 1.10.6. Concluding Remarks on Food Safety Factors
- 1.11. Developmental Aspects of Food Safety
- 1.12. Concluding remarks

**Consumer Perceptions of Food Safety** **244**

Janneke de Jonge, *Wageningen University, The Netherlands*  
 Ellen van Kleef, *Wageningen University, The Netherlands*  
 Lynn Frewer, *Wageningen University, The Netherlands*

- 1. Introduction
- 2. Consumer Perceptions of Risk
- 3. Risk and Benefit
  - 3.1. Risk and Benefit Associated with New Food Technologies
  - 3.2. The Negative Correlation Between Perceived Risk and Benefit
  - 3.3. Habit
  - 3.4. Risk Uncertainty and Variability
- 4. Trust in Food and Actors in the Food Chain
- 5. Individual Differences
- 6. Conclusion

**The Need For An International Approach – The Role Of FAO and WHO** **265**

Jorgen Schlundt, *Director, Department for Food Safety, Zoonoses and Foodborne diseases, World Health Organization, Geneva, Switzerland*  
 Kazuaki Miyagishima, *Secretary, Codex Alimentarius Commission, Joint FAO/WHO Food Standards Programme, Rome, Italy*

- 1. Introduction
- 2. Food Safety Risk Assessment at the International Level
  - 2.1. Joint FAO/WHO Expert Committee on Food Additives (JECFA)
  - 2.2. Joint FAO/WHO Meetings on Pesticide Residues (JMPR)
  - 2.3. Joint FAO/WHO Expert Meetings on Microbiological Risk Assessment (JEMRA)
- 3. Food Safety Risk Management at the International Level
  - 3.1. Codex Alimentarius Commission (CAC)
    - 3.1.1. Overview
    - 3.1.2. Legal Basis and Membership
    - 3.1.3. Organizational Structure and Strategic Planning
    - 3.1.4. Operation and Procedure
    - 3.1.5. International Standards and Related Texts
    - 3.1.6. Linkage with the World Trade Organization (WTO)
    - 3.1.7. Coordination with Other International Organizations
    - 3.1.8. Challenges
  - 3.2. International Food Safety Authorities Network (INFOSAN)

**Home Food Safety and Consumer Responsibility** **281**

Elizabeth C. Redmond, *Food Research and Consultancy Unit, University of Wales Institute Cardiff, Western Avenue, Cardiff, CF5 2YB, South Wales, UK.*  
 Christopher J. Griffith, *Food Research and Consultancy Unit, University of Wales Institute Cardiff, Western Avenue, Cardiff, CF5 2YB, South Wales, UK.*

- 1. Introduction
- 2. Incidence and cost of foodborne disease

3. Foodborne disease incidence associated with the home
4. Bacterial contamination and the domestic kitchen
5. The role of the consumer
6. Consumer food preparation and consumption patterns
7. Mechanisms for assessing consumer food safety behavior
8. Consumer knowledge of food safety issues
  - 8.1. Food Storage
  - 8.2. Cooking
  - 8.3. Cross Contamination During Food Preparation
  - 8.4. Hand Decontamination
9. Consumer attitudes to food safety in the home
  - 9.1. General and Specific Attitudes towards Food Safety
  - 9.2. Consumer Perceptions of Risk, Control and Responsibility
  - 9.3. Perception of the Home as a Location for Foodborne Disease
  - 9.4. Perception of Preferred Sources and Types of Information
10. Consumer food preparation behavior
  - 10.1. Behavioral Practices
  - 10.2. Self Report: Actual Behavior
11. Consumer food safety education
  - 11.1. Social Marketing
  - 11.2. Food Hygiene Initiatives
12. Conclusions

### **Management Of Food Safety In The Industrial Setting**

323

Yasmine Motarjemi, *Nestec, Vevey, Switzerland*

1. Introduction
2. Risks and Controls along the Food Supply Chain
  - 2.1. Environmental Contamination
  - 2.2. Raw Material (The focus of this section is on the hazards inherent to the raw material. Hazards contaminating the raw material are addressed in the next sections.)
  - 2.3. Primary Production
  - 2.4. Slaughter, Harvesting, Storage and Transport
  - 2.5. Processing and Manufacturing
  - 2.6. Retail and Distribution
  - 2.7. Food Preparation in Homes and in Food Service
3. Role of Food Technologies in Ensuring Food Safety
  - 3.1. Technologies Used For Rendering Food Safe
    - 3.1.1. Heat Treatment
    - 3.1.2. Non-thermal Technologies
  - 3.2. Technologies used to Control Contaminants
  - 3.3. Technologies to Prevent Re-Contamination during or after Processing
  - 3.4. Technologies to Support Food Analysis
  - 3.5. Technologies to Provide Support in Logistics and Supply Chain Management
  - 3.6. Emerging Technologies
4. Safety and Quality Assurance System
  - 4.1. Code of Good Practices
  - 4.2. HACCP
  - 4.3. Verification and Validation
  - 4.4. Traceability, Recall Procedure and Crisis Management
  - 4.5. Management Commitment, Human Resource Management and Training
5. Challenges and Outlook
  - 5.1. Changes Related to Internal Operations
  - 5.2. Changes in the Environment
6. Conclusions

**Food Safety At The National Level - The Role Of Governments**

**383**

Alan Reilly, Raymond Ellard, Judith O'Connor, *Food Safety Authority of Ireland, Lower Abbey Street, Dublin 1, Ireland*

1. Introduction
2. Threats to Food Safety
3. Food Safety – A Shared Responsibility
4. A Role for Government
5. Integrated Controls from Farm-to-Fork
6. Responsibilities for Food Control at Government Level
7. Food Laws and Regulations
8. Management of Official Food Controls
9. Inspection Services
10. Laboratories, Monitoring and Surveillance
11. Information, Education and Communication
12. Conclusion

**The Current Status and perspectives of the Vascular Surgery**

**394**

Piotr Andziak, *Department of General and Vascular Surgery, Central Clinical Hospital of the Ministry of Internal Affairs, Warsaw, Poland; Department of General and Vascular Surgery Medical University of Warsaw, Poland*

1. Introduction
2. Arterial Disease
  - 2.1. Surgery of carotid arteries
  - 2.2. Arteries of aortic arch
  - 2.3. Aneurysms in descending aorta.
  - 2.4. Thoracoabdominal aneurysms.
  - 2.5. Aneurysms of the abdominal aorta
  - 2.6. Aneurysms of the peripheral arteries.
  - 2.7. Surgical treatment of peripheral arterial occlusive disease (PAOD)
  - 2.8. Acute limb ischemia
  - 2.9. Arterial injuries
3. Venous Diseases
  - 3.1. Varicose Veins in lower limbs
  - 3.2. Treatments of the deep vein thrombosis.

**Progress in Pediatric Surgery - Selected Advances in Life Saving Procedures in Pediatric Surgery**

**412**

Piotr J. Kalicinski, *Department of Pediatric Surgery and Organ Transplantation, Children's Memorial Health Institute, Warsaw, Poland*

1. Introduction
2. Scope of Pediatric Surgery
3. Progress in Pediatric Surgery as a Result of New Life Saving Procedures and Technologies
4. Neonatal Surgery
  - 4.1. Introduction
  - 4.2. Fetal Surgery
    - 4.2.1. Types of Fetal Surgery
  - 4.3. FIGS Procedures
  - 4.4. FETENDO Procedures
  - 4.5. Open Fetal Surgery
  - 4.6. Summary of Fetal Surgery.
  - 4.7. ECMO as a Life Supporting System in Neonates with Respiratory Failure
  - 4.8. Technical Aspects of ECMO
  - 4.9. Complications of ECMO

- 4.10. Results of ECMO Therapy
5. Surgery in Children with Coagulopathy
6. Coagulation and Liver Diseases
  - 6.1. Coagulopathy
  - 6.2. Activated Recombinant Factor VII
  - 6.3. Summary of Coagulopathy in Liver Diseases
7. Other Advances in Bleeding Control and Hemostasis in Pediatric Surgery
8. Modern Liver Support or Substitution Possibilities in Children
9. Liver Transplantation as a Life Saving Procedure in Children with Liver Failure
  - 9.1. Indications for Liver Transplantation in Children
  - 9.2. Assessment of Liver Transplant Urgency in Children
  - 9.3. Advances in Surgical Techniques of Liver Transplantation in Children
  - 9.4. Results of Liver Transplantation in Children
10. Conclusions

### **Advances and Current Progress Of Liver Surgery**

428

Marek Krawczyk, *Medical University of Warsaw, Poland*

1. Introduction
2. Terminology
3. Liver resection
  - 3.1. Liver resection nomenclature
  - 3.2. New diagnostic possibilities
  - 3.3. Principles of liver resection
    - 3.3.1. Vascular control
    - 3.3.2. New surgical devices
4. Operative procedures
  - 4.1. Laparoscopic technique
  - 4.2. Management of the portal hypertension
5. Treatment of the most common liver lesions
  - 5.1. Benign tumors
    - 5.1.1. Cysts
      - 5.1.1.1. Solitary liver cysts
      - 5.1.1.2. Hydatoid cysts
    - 5.1.2. Haemangioma
    - 5.1.3. Focal nodular hyperplasia
    - 5.1.4. Adenoma
  - 5.2. Malignant tumors
    - 5.2.1. Hepatocellular carcinoma
    - 5.2.2. Cholangiocarcinoma (peripheral type)
    - 5.2.3. Secondary tumors

### **Gastrointestinal Fistulae: Lethal Implications Remain**

464

Amin Makram Ebeid, , *Dokki, Cairo Giza, Egypt*

1. Definition
2. Historical notes
3. Classification
  - 3.1. From an Anatomical Standpoint; GI Fistulas are Traditionally Classified as Internal or External
  - 3.2. Classification Based on the Loss of Fluid, Electrolytes and Proteins
  - 3.3. Classification According to Etiology
4. Etiology
  - 4.1. Spontaneous Fistulae Clearly Imply the Presence of an Underlying Pathology
  - 4.2. Acquired Fistulae
5. Evolution of the Management of Fistulae:- The MGH Experience
  - 5.1. The First Period (1945 - 1960)

- 5.2. The Second Period (1960 - 1970)
- 5.3. The Third Period (1970 -1975)
- 5.4. Preliminary Concluding Remarks
- 6. Management of gastrointestinal fistulae
  - 6.1. Stabilization
  - 6.2. Investigations
  - 6.3. Decision
  - 6.4. Definitive Therapy
  - 6.5. Healing Phase
- 7. Summary and Conclusions

**Social Participation in R&D: The Citizens Consensus Conferences** **482**  
 Alberto Pellegrini Filho, *Oswaldo Cruz Foundation, Rio de Janeiro, Brazil*

- 1. Introduction
- 2. Citizen’s participation in subjects of Science and Technology
- 3. The modalities and methodologies of citizen participation in R&D issues
- 4. The Citizens Consensus Conference (CCC)

**Financing Health Research: New Trends and Modalities** **496**  
 Andres De Francisco, *Global Forum for Health Research, Geneva, Switzerland.*

- 1. Introduction
- 2. Trends in health research financing
  - 2.1. Total funding and trends
  - 2.2. Public sector funding
  - 2.3. Private sector funding at the Global level
  - 2.4. Private not-for-profit
  - 2.5. Low- and middle-income countries
  - 2.6. Innovative developing countries
- 3. Financing for research on neglected diseases
  - 3.1. Investments in Malaria research
  - 3.2. Investments in HIV-AIDS research
    - 3.2.1. HIV vaccine research
    - 3.2.2. HIV Microbicide research
  - 3.3. Comparisons of disease burden and research funding
- 4. Public-Private Interactions: new modalities for financing neglected disease research
  - 4.1. Progress and concerns
- 5. Scientific production and financing
- 6. Challenges for future financing of health research

**Index** **525**

**About EOLSS** **531**